Vivos (RDGL) Cash from Operations Growth (3y) (2013 - 2025)
Vivos (RDGL) Cash from Operations Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.20 Bn | 175.91 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.87 Bn | 125.99 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 108.88 Bn | 99.66 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 68.33 Bn | 66.87 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 47.31 Bn | 43.64 Bn | 1.29 Bn | -48.14% |
| 6 | Dexcom | 28.65 Bn | 27.53 Bn | 750.30 Mn | 50.11% |
| 7 | GE HealthCare Technologies | 28.40 Bn | 26.11 Bn | 1.98 Bn | -14.75% |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - | - |
| 9 | Koninklijke Philips | 25.55 Bn | 22.42 Bn | 2.07 Bn | 0.50% |
| 10 | Vivos | 27.57 Mn | 26.01 Mn | -3,105.00 | -24.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24.19% |
| Sep 30, 2025 | -17.45% |
| Jun 30, 2025 | -52.30% |
| Mar 31, 2025 | -5.81% |
| Dec 31, 2024 | -25.99% |
| Sep 30, 2024 | -41.66% |
| Jun 30, 2024 | -0.78% |
| Mar 31, 2024 | -20.06% |
| Dec 31, 2023 | -8.20% |
| Sep 30, 2023 | -6.46% |
| Jun 30, 2023 | -9.55% |
| Mar 31, 2023 | -49.86% |
| Dec 31, 2022 | -3.62% |
| Sep 30, 2022 | -15.23% |
| Jun 30, 2022 | -10.37% |
| Mar 31, 2022 | -12.25% |
| Dec 31, 2021 | 23.82% |
| Sep 30, 2021 | -35.91% |
| Jun 30, 2021 | -92.62% |
| Mar 31, 2021 | -61.40% |